"I think this is a meaningful study in that the third-generation EGFR TKI treatment, such as Lazertinib, showed data related to brain metastasis, but clearly focused on the intracranial response to confirm the effect." When brain metastasis occurs in non-small cell lung cancer patients using 1st or 2nd generation EGFR TKI agents, most patients' condition deteriorates rapidly, and furthermore, in the case of T790M negative, options are limited. A new therapeutic basis has emerged.

A domestic phase 2 study that confirmed the effect of Lazertinib, the third generation, on patients with brain metastasis after failure of the existing 1st or 2nd generation EGFR TKI drugs in EGFR mutated non-small cell lung cance